Abstract:Modern drug design aims to discover novel lead compounds with attractable chemical profiles to enable further exploration of the intersection of chemical space and biological space. Identification of small molecules with good ligand efficiency, high activity, and selectivity is crucial toward developing effective and safe drugs. However, the intersection is one of the most challenging tasks in the pharmaceutical industry, as chemical space is almost infinity and continuous, whereas the biological space is very limited and discrete. This bottleneck potentially limits the discovery of molecules with desirable properties for lead optimization. Herein, we present a new direction leveraging posttranslational modification (PTM) protein isoforms target space to inspire drug design termed as "Post-translational Modification Inspired Drug Design (PTMI-DD)." PTMI-DD aims to extend the intersections of chemical space and biological space. We further rationalized and highlighted the importance of PTM protein isoforms and their roles in various diseases and biological functions. We then laid out a few directions to elaborate the PTMI-DD in drug design including discovering covalent binding inhibitors mimicking PTMs, targeting PTM protein isoforms with distinctive binding sites from that of wild-type counterpart, targeting protein-protein interactions involving PTMs, and hijacking protein degeneration by ubiquitination for PTM protein isoforms. These directions will lead to a significant expansion of the biological space and/or increase the tractability of compounds, primarily due to precisely targeting PTM protein isoforms or complexes which are highly relevant to biological functions. Importantly, this new avenue will further enrich the personalized treatment opportunity through precision medicine targeting PTM isoforms.

Design of bifunctional molecules to accelerate post-translational modifications: achievements and challenges

Investigation of Protein Post-Translational Modifications with Site-Specifically Incorporated Non-Canonical Amino Acids

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

An Artificial Protein Modulator Reprogramming Neuronal Protein Functions

Harmony of Protein Tags and Chimeric Molecules Empowers Targeted Protein Ubiquitination and Beyond

Drug design targeting active posttranslational modification protein isoforms

Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors

Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications

Dynamics of Post-Translational Modification Inspires Drug Design in the Kinase Family

Research Progress in Protein Post-Translational Modification

Unraveling the battle for lysine: A review of the competition among post-translational modifications

Expanding the Horizons of Targeted Protein Degradation: A Non-Small Molecule Perspective

New Opportunities and Challenges of Smart Polymers in Post-Translational Modification Proteomics

Targeted Protein Posttranslational Modifications by Chemically Induced Proximity for Cancer Therapy

Chemistries of bifunctional PROTAC degraders

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

Targeted Biomolecule Regulation Platform: A Split-and-Mix PROTAC Approach

Precise Modulation of Protein Degradation by Smart PROTACs

Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies

Protein posttranslational modifications in metabolic diseases: basic concepts and targeted therapies

Protein post-translational modifications in the regulation of cancer hallmarks